Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV000020437 | SCV000883711 | pathogenic | Smith-Lemli-Opitz syndrome | 2020-02-03 | criteria provided, single submitter | clinical testing | The DHCR7 c.506C>T, p.Ser169Leu variant (rs80338855) has been reported in multiple patients diagnosed with Smith-Lemli-Opitz syndrome (Correa-Cerro 2005, Witsch-Baumgartner 2000), and found with another pathogenic variant in one individual (Yu 2000). It is listed in ClinVar (Variation ID: 21274), and is observed in the general population databases at a frequency of 0.008 percent in the Exome Variant Server (1/12988 alleles), and 0.005 percent in the Genome Aggregation Database (12/245720 alleles). Based on the high frequency of this variant in published reports of Smith-Lemli-Opitz syndrome, the p.Ser169Leu variant is classified as pathogenic. References: Correa-Cerro L et al. 3beta-hydroxysterol Delta7-reductase and the Smith-Lemli-Opitz syndrome. Mol Genet Metab. 2005; 84(2):112-26. Witsch-Baumgartner M et al. Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet. 2000; 66(2):402-12. Yu H et al. Spectrum of Delta(7)-dehydrocholesterol reductase mutations in patients with the Smith-Lemli-Opitz (RSH) syndrome. Hum Mol Genet. 2000; 9(9):1385-91. |
Illumina Laboratory Services, |
RCV000020437 | SCV000915552 | uncertain significance | Smith-Lemli-Opitz syndrome | 2017-11-26 | criteria provided, single submitter | clinical testing | The DHCR7 c.506C>T (p.Ser169Leu) missense variant has been reported in at least three studies in which it is found in a total of four individuals with Smith-Lemli-Opitz syndrome (SLOS) in a compound heterozygous state and in nine out of 1,037 disease-associated alleles, none of which were homozygotes, however further details of zygosity are not given (Bianconi et al. 2011; Sparks et al. 2014; Boland et al. 2016; Eroglu et al. (2017). The second variant in the compound heterozygotes was not stated in two of the individuals, was an intron variant in one individual with a mild phenotype and normal IQ and a splice region/intron variant in the fourth individual. The p.Ser169Leu variant is described as one of the 12 most frequent disease-causing variants found at a frequency of 1.7% in patients with SLOS (a total of 10 alleles) (Correa-Cerro et al. 2005; Nowaczyk et al. 2013). Control data are unavailable for this variant, which is reported at a frequency of 0.00012 in the European (non-Finnish) population of the Exome Aggregation Consortium. Based on the evidence, the p.Ser169Leu variant is classified as a variant of unknown significance but suspicious for pathogenicity for Smith-Lemli-Opitz syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Baylor Genetics | RCV000020437 | SCV001163333 | pathogenic | Smith-Lemli-Opitz syndrome | 2022-09-29 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000020437 | SCV001194041 | likely pathogenic | Smith-Lemli-Opitz syndrome | 2019-12-09 | criteria provided, single submitter | clinical testing | NM_001360.2(DHCR7):c.506C>T(S169L) is classified as likely pathogenic in the context of Smith-Lemli-Opitz syndrome. Sources cited for classification include the following: PMID 15464432, 10814720, 22226660, 22391996, 21990131 and 10677299. Classification of NM_001360.2(DHCR7):c.506C>T(S169L) is based on the following criteria: This variant has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000020437 | SCV001372248 | pathogenic | Smith-Lemli-Opitz syndrome | 2020-06-14 | criteria provided, single submitter | clinical testing | Variant summary: DHCR7 c.506C>T (p.Ser169Leu) results in a non-conservative amino acid change located in the Transmembrane domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 250928 control chromosomes. c.506C>T has been reported in the literature in multiple individuals affected with Smith-Lemli-Opitz Syndrome (example, Yu_2000, Witsch-Baumgartner_2000, Bianconi_2011, Roullet_2012, Quelin_2012, Eroglu_2017). These data indicate that the variant is very likely to be associated with disease. One publication reports experimental evidence evaluating an impact on protein function, however, does not allow convincing conclusions about the variant effect due to the compound heterozygous genotype of the cell line evaluated (Ginat_2004). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (Pathogenic, n=1; Likely pathogenic, n=2; VUS, n=1). Some submitters have cited overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as pathogenic. |
Invitae | RCV000020437 | SCV001378784 | pathogenic | Smith-Lemli-Opitz syndrome | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 169 of the DHCR7 protein (p.Ser169Leu). This variant is present in population databases (rs80338855, gnomAD 0.008%). This missense change has been observed in individual(s) with Smith-Lemli-Opitz syndrome (PMID: 10814720, 15896653, 21990131, 22226660, 22391996). ClinVar contains an entry for this variant (Variation ID: 21274). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt DHCR7 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Genetic Services Laboratory, |
RCV001818169 | SCV002064488 | likely pathogenic | not provided | 2017-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002345251 | SCV002645935 | pathogenic | Inborn genetic diseases | 2018-01-26 | criteria provided, single submitter | clinical testing | The p.S169L pathogenic mutation (also known as c.506C>T), located in coding exon 4 of the DHCR7 gene, results from a C to T substitution at nucleotide position 506. The serine at codon 169 is replaced by leucine, an amino acid with dissimilar properties. This mutation has been identified in conjunction with a second DHCR7 alteration in multiple individuals with Smith-Lemli-Opitz syndrome (Witsch-Baumgartner M et al. Am. J. Hum. Genet., 2000 Feb;66:402-12; Yu H et al. Hum. Mol. Genet., 2000 May;9:1385-91; Ginat S et al. Mol. Genet. Metab., 2004;83:175-83; Bianconi SE et al. Am. J. Med. Genet. A, 2011 Nov;155A:2732-8; Roullet JB et al. J. Inherit. Metab. Dis., 2012 Sep;35:859-69). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
Genetics and Molecular Pathology, |
RCV000020437 | SCV002761423 | pathogenic | Smith-Lemli-Opitz syndrome | 2021-11-08 | criteria provided, single submitter | clinical testing | The DHCR7 c.506C>T variant is a single nucleotide change in exon 6/9 of the DHCR7 gene, which is predicted to change the amino acid serine at position 169 in the protein to leucine. The variant is rare in gnomAD (1/152,224 heterozygotes, 0 homozygotes) (PM2). This variant is detected in trans with the pathogenic DHCR7:c.964-1G>C variant in this patient. The same compound heterozygous genoype has also been reported in at least two other families with a confirmed diagnosis of Smith-Lemli-Opitz syndrome (PMID: 27401223) (PM3_strong). The variant has been identified in at least 7 probands with a clinical presentation of Smith-Lemli-Opitz syndrome; this represents a significant increase in the prevalence of the variant in affected individuals compared with the prevalence in control subjects (PS4_strong). The variant has been reported as pathogenic by other diagnostic laboratories (ClinVar Variation ID: 21274) and has been reported in the HGMD database: CM001124. Computational predictions support a deleterious effect on the gene or gene product (PP3). |
Revvity Omics, |
RCV000020437 | SCV004234301 | pathogenic | Smith-Lemli-Opitz syndrome | 2023-07-18 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000020437 | SCV000040851 | not provided | Smith-Lemli-Opitz syndrome | no assertion provided | literature only | ||
Natera, |
RCV000020437 | SCV002093043 | pathogenic | Smith-Lemli-Opitz syndrome | 2021-03-19 | no assertion criteria provided | clinical testing |